DR. STEVEN G BLACK OD
Prescription History 1063464949
Optometrist in Terre Haute, IN


Quality Rating: 7.5 out of 100 score

NPI Status: Active since May 17, 2006

Contact Information

4424 S 7TH ST
TERRE HAUTE, IN
ZIP 47801
Phone: (812) 299-3937
Fax: (812) 299-8670

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. STEVEN G BLACK OD, an active Optometrist specialist practicing in Terre Haute, IN. Our medical registry currently tracks 10 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 788 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 415 claims alone.


Brimonidine Tartrate

Generic Formulation: Brimonidine TartrateSpecialty: Optometry
Provider Metrics Summary
Total Claims 38
30-Day Fills 72.0
Days Supply 2,121
IN State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills96.2
Peer Average Days Supply2,788
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,864.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$75.38

State Avg Cost Per Claim

$40.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Dorzolamide Hcl

Generic Formulation: Dorzolamide HclSpecialty: Optometry
Provider Metrics Summary
Total Claims 79
30-Day Fills 109.3
Days Supply 3,215
IN State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills93.2
Peer Average Days Supply2,777
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 75.6% higher than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,727.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$21.86

State Avg Cost Per Claim

$30.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dorzolamide is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. It belongs to a class of drugs known as carbonic anhydrase inhibitors.

Dorzolamide-Timolol

Generic Formulation: Dorzolamide Hcl/Timolol MaleatSpecialty: Optometry
Provider Metrics Summary
Total Claims 48
30-Day Fills 90.8
Days Supply 2,676
IN State Average Benchmarks
Peer Average Claims66.0
Peer Average 30-Day Fills144.5
Peer Average Days Supply4,317
Conservative Utilization

This provider writes prescriptions for this formulation 27.3% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,063.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.16

State Avg Cost Per Claim

$32.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers, and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors.

Erythromycin

Generic Formulation: Erythromycin BaseSpecialty: Optometry
Provider Metrics Summary
Total Claims 25
30-Day Fills 25.0
Days Supply 514
IN State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills42.1
Peer Average Days Supply621
Conservative Utilization

This provider writes prescriptions for this formulation 37.5% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $253.77 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.15

State Avg Cost Per Claim

$26.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Erythromycin is used to treat a wide variety of bacterial infections. It may also be used to prevent certain bacterial infections. Erythromycin is known as a macrolide antibiotic. It works by stopping the growth of bacteria. This antibiotic treats or prevents only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 415
30-Day Fills 845.2
Days Supply 24,502
IN State Average Benchmarks
Peer Average Claims121.0
Peer Average 30-Day Fills234.6
Peer Average Days Supply6,777
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 243.0% higher than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,606.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$20.74

State Avg Cost Per Claim

$23.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Neomycin-Polymyxin-Dexameth

Generic Formulation: Neomycin/Polymyxin B/DexamethaSpecialty: Optometry
Provider Metrics Summary
Total Claims 19
30-Day Fills 21.1
Days Supply 402
IN State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills31.4
Peer Average Days Supply494
Conservative Utilization

This provider writes prescriptions for this formulation 36.7% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $254.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.39

State Avg Cost Per Claim

$13.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat conditions involving swelling (inflammation) of the eyes and to treat or prevent bacterial eye infections. This product contains neomycin and polymyxin, antibiotics that work by stopping the growth of bacteria. It also contains dexamethasone, an anti-inflammatory corticosteroid that works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections and may worsen them (such as infections caused by viruses, fungi, mycobacteria). Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Prednisolone Acetate

Generic Formulation: Prednisolone AcetateSpecialty: Optometry
Provider Metrics Summary
Total Claims 11
30-Day Fills 15.7
Days Supply 386
IN State Average Benchmarks
Peer Average Claims87.0
Peer Average 30-Day Fills112.8
Peer Average Days Supply2,897
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 87.4% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $579.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$52.70

State Avg Cost Per Claim

$49.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain eye conditions due to inflammation or injury. Prednisolone works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs known as corticosteroids.

Restasis

Generic Formulation: CyclosporineSpecialty: Optometry
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 570
IN State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills58.9
Peer Average Days Supply1,715
Conservative Utilization

This provider writes prescriptions for this formulation 42.4% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,165.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$692.93

State Avg Cost Per Claim

$1,117.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Optometry
Provider Metrics Summary
Total Claims 97
30-Day Fills 207.3
Days Supply 6,171
IN State Average Benchmarks
Peer Average Claims11.0
Peer Average 30-Day Fills19.0
Peer Average Days Supply555
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 781.8% higher than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,142.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.78

State Avg Cost Per Claim

$561.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Xiidra

Generic Formulation: LifitegrastSpecialty: Optometry
Provider Metrics Summary
Total Claims 37
30-Day Fills 45.0
Days Supply 1,350
IN State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills38.6
Peer Average Days Supply1,162
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 60.9% higher than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $33,597.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$908.03

State Avg Cost Per Claim

$1,089.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat dry eye disease.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. STEVEN G BLACK OD provides transparency into local medical care patterns within Terre Haute, IN.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.